There hasn't been any alzheimer's drug approved in the past 20 yrs, let alone one with high efficacy The only other competitor, Biogen, has stopped phase 3 trials of aducanumab
Why suddenly all want to study about the LUCIDITY only? Actually the casino business is more attractive, take a look at GenM if you have the time. Huat Huat Treasure Hunt!
Taurx 0.7% shareholder here. Dont badmouth my company. This drug is the real deal. The first disease modifying drug that can significantly slowdown disease progression in a phase 3 trial. I can talk a lot of Alzheimer’s drug industry landscape, tau vs amyloid theory, taurx valuation, competitors, etc. I know the real valuation of taurx.
@AngTayKor... please, do a youtube collab with me, and talk about Alzheimer's drug landscape! I was trying to do a video talking about Taurx but I have to admit that I was simply relying on google for my research... would be good to have someone who actually knows the field in depth to discuss on my channel!
@DestinyL .... I just checked (in my video!) ... 2016 genting bhd had a 20.7% stake, which has been diluted to... 20.3% stake now. So, slight dilution, but not much.
2016 Kenanga report on additional value coming from Taurx. RM3.31/SHARE
Hence all IB's TP need to add another RM3? Revising TP to RM9.00? Even after 40% holding co. discount, IB also need to add RM2.00(Contribution from Taurx) to their previous TP, which projected to be RM8++? :D
Told u dy. It was a con job to distribute shares yesterday.
Thosands buy n sell orders gone. Tawke already packed up n left. As more n more people exit to cut loss, price will fall. The earlier you head for the door the better.
I just now sold another 25% of my G. I am still holding my 25% of G. Can’t let profits slip by without doing anything. Sorry I heed Sifu ATK advice—- SAFETY FIRST.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
DestinyL
4,746 posts
Posted by DestinyL > 2022-06-01 22:35 | Report Abuse
There hasn't been any alzheimer's drug approved in the past 20 yrs, let alone one with high efficacy
The only other competitor, Biogen, has stopped phase 3 trials of aducanumab
https://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials